Dublin, Aug. 22, 2022 (GLOBE NEWSWIRE) -- The "Global Neurostimulation Devices Market, by Device Type, by Application, by End-user, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's offering. The global neurostimulation devices market held a market value of USD 7,622.7 Million in 2021 and is estimated to reach USD 17,367.0 Million by the year 2030. The market is anticipated to register a CAGR of 9.7% during the forecast period. A neurostimulation device comprises a neurostimulator which generates the electrical impulses, leads constituting insulated medical wires to deliver electrical pulses, and a patient's handheld device. The ideal calibration of all components leads to an effective patient wellbeing response to the neuro disorder. The increasing neurological diseases across the globe, rising clinical trials for neurostimulation devices, investments by companies, are driving factor for the growth of the neurostimulation devices market. in addition to that, the advancements in technologies, including silicon micro-fabrication and wireless energy transfer, propel the market growth. On the other hand, the high cost to end user is a restrictive factor for neurostimulation devices market. Also, according Sandvik Material Technology survey, regarding the challenges during the medical device design phase, 20% of respondents stated that a common issue was to meet deadlines due to lack of resources.in light of this, the expertise in metal alloy materials and insulation coating is vital for engineering a medical-wire component customised for pain management devices. Thus, such factors hinder the market growth. Growth Influencers:
Increasing number of incidences related to Neurological disorders
The rising number of cases of neurological diseases demand for top-notch neurostimulation devices drive the market growth. For instance, according to the statistics published by the American Academy of Neurology, Alzheimer has been ranked as the sixth-leading cause of death, and Parkinson's affects approximate 1 Million Americans with at least 60,000 new cases annually. Overall, such increase in incidence rate is projected to drive the market in the coming years. Investment for Neurological R&D
The prominent players are investing in clinical trials to sustain their products in the industry. For instance, Boston Scientific Corporation is running a clinical trial study investigating patient satisfaction with treatment using a new implantable neurostimulation system for chronic pain of the trunk and/or limbs. Such a factor aids significantly in increasing the growth rate of the neurostimulation devices market
Key players operating in the global neurostimulation devices market include Abbott Laboratories, Advanced Bionics, B. Braun Melsungen AG, Boston Scientific Corporation, BrainsWay, Cochlear, CONMED Corporation, KONINKLIJKE PHILIPS, Laborie Medical Technologies, Inc., MED-EL Medical Electronics, Medtronic PLC, Nevro Corp, Zimmer Biomet Holdings, Inc. among others. The major four players in the market hold approximately 55% of the market share. These market players are investing in product launches, collaborations, mergers & acquisitions, and expansions to create a competitive edge in the market. For instance, in January 2021, Abbott launched NeuroSpher myPath, a digital health app to track and report on patient perceived pain relief and well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. Thus, such initiatives propel the market growth. The global neurostimulation devices market report provides insights on the below pointers:
Market Penetration: Provides comprehensive information on the market offered by the prominent players
Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the global neurostimulation devices market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
Pricing Analysis: Pricing analysis of various types and other components used in the manufacturing of neurostimulation devices
Manufacturing Cost Analysis: Cost-share of various neurostimulation devices materials, cost analysis of neurostimulation devices materials, Unit Cost Analysis of neurostimulation devices materials
New Advancement in Neurostimulation Devices:
The global neurostimulation devices market report answers questions such as:
What is the market size and forecast of the global neurostimulation devices market?
What are the inhibiting factors and impact of COVID-19 on the global neurostimulation devices market during the assessment period?
Which are the products/segments/applications/areas to invest in over the assessment period in the global neurostimulation devices market?
What is the competitive strategic window for opportunities in the global neurostimulation devices market?
What are the technology trends and regulatory frameworks in the global neurostimulation devices market?
What is the market share of the leading players in the global neurostimulation devices market?
What modes and strategic moves are considered favorable for entering the global neurostimulation devices market?
Chapter 3. Executive Summary: Global Neurostimulation Device Market
Chapter 4. Global Neurostimulation Device Market Overview 4.1. Industry Value Chain Analysis 4.1.1. Material Provider 4.1.2. Manufacturer 4.1.3. Distribution 4.1.4. End User 4.2. Industry Outlook 4.2.1. New Advancement in Neurostimulation Device 4.3. PESTLE Analysis 4.4. Porter's Five Forces Analysis 4.4.1. Bargaining Power of Suppliers 4.4.2. Bargaining Power of Buyers 4.4.3. Threat of Substitutes 4.4.4. Threat of New Entrants 4.4.5. Degree of Competition 4.5. Market Dynamics and Trends 4.5.1. Growth Drivers 4.5.2. Restraints 4.5.3. Challenges 4.5.4. Key Trends 4.6. Covid-19 Impact Assessment on Market Growth Trend 4.7. Market Growth and Outlook 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 - 2030 4.7.2. Market Volume Estimates and Forecast (000' Units), 2017 - 2030 4.7.3. Price Trend Analysis, By Device Type 4.8. Competition Dashboard 4.8.1. Market Concentration Rate 4.8.2. Company Market Share Analysis (Value %), 2020 4.8.3. Competitor Mapping
Chapter 5. Neurostimulation Device Market Analysis, By Product 5.1. Key Insights 5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn & 000' Units) 5.2.1. Implantable Device 5.2.1.1. Cochlear Implants (CI) 5.2.1.2. Sacral Nerve Stimulation (SNS) 5.2.1.3. Gastric Electric Stimulation (GES) 5.2.1.4. Deep Brain Stimulation (DBS) 5.2.1.5. Vagus Nerve Stimulation (VNS) 5.2.1.6. Spinal Cord Stimulation (SCS). 5.2.2. External Device 5.2.2.1. Transcranial Magnetic Stimulation (TMS) 5.2.2.2. Transcutaneous Electrical Nerve Stimulation (TENS)
Chapter 6. Neurostimulation Device Market Analysis, By Application 6.1. Key Insights 6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn & 000' Units) 6.2.1. Pain Management 6.2.2. Hearing Loss 6.2.3. Urinary Incontinence 6.2.4. Parkinson's Disease 6.2.5. Epilepsy 6.2.6. Gastroparesis 6.2.7. Depression 6.2.8. Others
Chapter 7. Neurostimulation Device Market Analysis, By End User 7.1. Key Insights 7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn & 000' Units) 7.2.1. Hospitals/Clinics 7.2.2. Cognitive Care Centers 7.2.3. Research Institutes 7.2.4. Others
Chapter 8. Neurostimulation Device Market Analysis, By Region
Chapter 9. North America Neurostimulation Device Market Analysis
Chapter 10. Europe Neurostimulation Device Market Analysis
Chapter 11. Asia Pacific Neurostimulation Device Market Analysis
Chapter 12. Middle East and Africa Neurostimulation Device Market Analysis
Chapter 13. South America Neurostimulation Device Market Analysis
Chapter 14. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook) 14.1. Abbott Laboratories 14.2. Advanced Bionics 14.3. B. Braun Melsungen AG 14.4. Boston Scientific Corporation 14.5. BrainsWay 14.6. Cochlear 14.7. CONMED Corporation 14.8. KONINKLIJKE PHILIPS 14.9. Laborie Medical Technologies, Inc. 14.10. MED-EL Medical Electronics 14.11. Medtronic PLC 14.12. Nevro Corp 14.13. Zimmer Biomet Holdings, Inc. 14.14. Other Prominent Players
For more information about this report visit https://www.researchandmarkets.com/r/3x4t5v
As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t
Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.
Advanced Micro Devices, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $AMD performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.
It's time to be extra picky.
Congressional Democrats want to slam shut a tax loophole known as the "backdoor" Roth IRA. In one of several proposed changes that target the retirement accounts of wealthy Americans, Democrats on the House Ways and Means Committee want to prohibit people … Continue reading → The post Democrats Want to End This Lucrative Retirement Account Loophole appeared first on SmartAsset Blog.
A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last two months, and at least one strategist believes that the market won’t be testing those lows again this year. JPMorgan's Jason Hunter believes that inflation may have peaked, and that the upcoming CPI report will provide additional evidence of that. “We
AT&T income-hungry shareholders should have seen it coming. In April last year, a month before announcing the spinoff of its media division to shareholders in the form of shares of a 71% stake in the newly created Warner Bros. Discovery Chief Executive Officer John Stankey assured investors that “our deliberate capital-allocation plan allowed us to invest and sustain our dividend at current levels, which we believe is attractive.” AT&T’s eventual failure to raise the dividend in 2021 broke a 34-year streak and saw it booted out of the vaunted S&P 500 Dividend Aristocrats Index.
(Bloomberg) -- In a week that saw discretionary buyers beat a quick retreat from risky assets, another set of traders stood up to halt a three-week plunge in the S&P 500: those with little choice but to buy.Most Read from BloombergCharles Becomes King as the Face of a Nation ChangesDouble Rainbow Appears Over Buckingham Palace as Crowd Gathers to Mourn QueenUkraine Army’s Breakthrough in North Threatens Russian GripQueen Elizabeth’s Doctors Are Concerned for Her HealthQueen Elizabeth II, Britain
Baron Funds, an asset management firm, published its “Baron Durable Advantage Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. Baron Durable Advantage Fund (the “Fund”) declined 15.7% (Institutional Shares) during the second quarter, roughly in line with the 16.1% decline for the S&P 500 Index (the “Index”), the […]
Fintech stocks were crushed during the market's decline this year. Thus, they tend bounce harder on recoveries.
Expect cost certainty to fly right out the (drafty) window.
In this article, we will look at 10 stocks that Jim Cramer is talking about in September. If you want to explore more stocks that journalist investor, Jim Cramer, is talking about in September, you can also take a look at Jim Cramer is Talking About These 5 Stocks in September. Jim Cramer has acquired […]
It’s time to consider this contrarian play.
Investors are seeing higher growth potential for QuantumScape's battery cell technology after an interesting EV industry development.
Amazon.com Inc founder Jeff Bezos made an early bet on the short-term rental platform Airbnb Inc during the company’s Series B round in 2011, nearly a decade before its initial public offering (IPO). His investment came long before the now popular accommodations marketplace was a household name and a common term used to describe virtually any short-term rental. It’s unclear exactly how much Bezos profited off his pre-IPO investment in Airbnb, but it’s clear that the billionaire investor had incr
In an effort to streamline the regulation that governs how retirement accounts can be used, the IRS has proposed a change for 403(b) plans - a type of workplace retirement plan use mostly by public and non-profit employees. Employer-sponsored plans … Continue reading → The post The IRS Is Changing How Your Beneficiaries Receive Your Retirement Funds appeared first on SmartAsset Blog.
Wall Street firm BofA Securities on Friday identified seven semiconductor stocks that it believes can withstand the current market downturn.
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
A Porsche public offering could value the company at almost the entire market cap of VW. And that’s just one of VW’s attractions.